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Abstract
Alcohol consumption is one of the leading causes of the global burden of disease 
and results in high healthcare and economic costs. Heavy alcohol misuse leads to 
alcohol-related liver disease, which is responsible for a significant proportion of 
alcohol-attributable deaths globally. Other than reducing alcohol consumption, 
there are currently no effective treatments for alcohol-related liver disease. 
Oxidative stress refers to an imbalance in the production and elimination of 
reactive oxygen species and antioxidants. It plays important roles in several 
aspects of alcohol-related liver disease pathogenesis. Here, we review how 
chronic alcohol use results in oxidative stress through increased metabolism via 
the cytochrome P450 2E1 system producing reactive oxygen species, acetaldehyde 
and protein and DNA adducts. These trigger inflammatory signaling pathways 
within the liver leading to expression of pro-inflammatory mediators causing 
hepatocyte apoptosis and necrosis. Reactive oxygen species exposure also results 
in mitochondrial stress within hepatocytes causing structural and functional 
dysregulation of mitochondria and upregulating apoptotic signaling. There is also 
evidence that oxidative stress as well as the direct effect of alcohol influences 
epigenetic regulation. Increased global histone methylation and acetylation and 
specific histone acetylation inhibits antioxidant responses and promotes 
expression of key pro-inflammatory genes. This review highlights aspects of the 
role of oxidative stress in disease pathogenesis that warrant further study 
including mitochondrial stress and epigenetic regulation. Improved 
understanding of these processes may identify novel targets for therapy.
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Core tip: Alcohol is a global health problem with alcohol-related liver disease forming a 
significant proportion of alcohol-attributable deaths. However, there are no effective 
treatments for alcohol-related liver disease. Oxidative stress plays multiple roles in disease 
pathogenesis, which if better understood may yield new therapeutic targets. Here, we 
review the current literature on how alcohol consumption leads to oxidative stress and how 
this results in hepatocyte apoptosis and necrosis through its contribution to mitochondrial 
stress, dysregulation of cell signalling pathways and epigenetic regulation.
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Europe has the highest per capita alcohol consumption and alcohol-related loss of 
disability adjusted life years globally[1]. The European Union is the heaviest drinking 
region of the world, with 11 liters of pure alcohol drunk per adult each year[1]. In the 
last decade, this trend continues to rise in central and northern Europe. Alcohol is a 
dose-related risk factor for more than 200 diseases[1]. It causes 5.9% of all deaths 
globally and more than 25% of deaths in the age group 20-39 years[1].
Heavy alcohol use is the cause of alcohol-related liver disease (ALD). Therefore, it is 
not surprising that the incidence of ALD is on a rising trajectory[2]. The scale of ALD is 
estimated to burden the United Kingdom national health system with health-related 
costs of over £3.5 billion per year[2]. In Europe, the cost of treating ALD is estimated to 
be €17 billion, together with €5bn spent on treatment and prevention of harmful 
alcohol use and alcohol dependence[3]. Worldwide, alcohol-related liver cirrhosis 
deaths account for approximately 10% of all alcohol-attributable deaths resulting in 
the loss of 22.2 million disability-adjusted life years annually[4].
The ALD spectrum ranges from simple steatosis to steatohepatitis, fibrosis, and 
cirrhosis. While alcohol-related cirrhosis is no longer considered a completely 
irreversible condition, no effective anti-fibrotic therapies are currently available. 
Cirrhosis can be divided into compensated and decompensated stages, with 
differentiating clinical features and prognosis. The median survival of patients with 
compensated liver disease is approximately 6.5 years but only 2.5 years in those with 
decompensated cirrhosis[4]. Once a complication of cirrhosis develops, the 5-year 
survival rate decreases to less than 20%[4].
Alcoholic hepatitis (AH) is an acute inflammatory condition that occurs on the 
background of ALD. Severe AH has a mortality rate of 30% within 3 mo[5] but even 
non-severe AH has a significant 7% mortality within 3 mo[6]. The established treatment 
for AH is corticosteroids, which improve short-term survival but do not affect long-
term survival[5].
The molecular mechanisms underlying ALD pathogenesis are complex and have 
not been fully elucidated. However, there is emerging evidence that oxidative stress 
plays a role in mediating the inflammatory response and in directly causing liver 
damage. Oxidative stress represents the body’s imbalance in the production and the 
elimination of reactive species (including reactive oxygen and nitrogen species) as well 
as decreased production of antioxidants[7]. Here, we review the role of oxidative stress 
in ALD focusing on its effect on mitochondrial stress, cell signaling and epigenetic 
regulation.
LITERATURE SEARCH
Comprehensive searches of MEDLINE, EMBASE, PubMed and TRIPS from their 
commencement to June 2019 were conducted. The search strategy included subject 
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headings and keywords related to “alcohol” and “oxidative stress” and “liver”. The 
reference list of all included studies was screened for eligibility. This review included 
all study types in humans and animals. Studies published in all languages were 
considered. One author independently screened titles and abstracts and subsequently 
reviewed full-texts of retrieved studies for eligibility.
ALCOHOL METABOLISM
Alcohol (ethanol) is metabolized by three major pathways (Figure 1)[7]. The primary 
pathway is initiated by alcohol dehydrogenase (ADH), a NAD+ requiring enzyme 
expressed at high levels in hepatocytes, which oxidizes ethanol to acetaldehyde[7]. In a 
normal liver, acetaldehyde enters the mitochondria and is quickly metabolized to 
acetate by aldehyde dehydrogenase (ALDH). Acetate is then broken down to carbon 
dioxide and water for elimination[8]. In chronic alcohol users, the ADH/ALDH 
pathway becomes saturated and reactive aldehydes are produced from the metabolism 
process such as malondialdehyde-acetaldehyde (MAA), 4-hydroxy-2-nonenal (HNE) 
and lipid hydroperoxides which can bind to proteins to produce protein adducts[8].
These protein adducts are capable of provoking an immune response. In vitro 
experiments showed that the viability of antigen-presenting cells, lymphocytes, and 
hepatocytes was decreased on incubation with an MAA hen egg lysosome adduct[9]. 
Circulating antibodies against MAA protein adducts were increased in patients with 
ALD and AH and correlated with the severity of liver injury[9].
The second major pathway to metabolise ethanol is the microsomal ethanol 
oxidizing system (MEOS), which involves an NADPH-requiring enzyme, the 
cytochrome P450 enzyme CYP2E1[10], which is induced by chronic alcohol 
exposure[11,12]. The increase of CYP2E1 after alcohol intake is due to stabilization of 
CYP2E1 rather than to a de novo synthesis[11]. The MEOS pathway metabolises ethanol 
to acetaldehyde by converting NADPH+ and O2 to NADP and H2O resulting in the 
generation of reactive oxygen species (ROS). CYP2E1 plays a role in lipid peroxidation, 
protein oxidation, and protein nitration (Figure 1)[11]. It is also known to promote 
hepatic carcinogenesis by oxidizing DNA in alcohol-exposed rodents[13].
Ethanol metabolism through CYP2E1 not only produces acetaldehyde but also 
generates ROS including H2O2, hydroxyl (OH-) and carbon centered OH- (Figure 1)[14]. 
These ROS may be neutralized by a potent antioxidant defense system[14]. However, 
chronic alcohol consumption disrupts this system; depletion of mitochondrial 
glutathione (GSH) is observed in patients with alcohol dependence[15], which impairs 
hepatocyte tolerance to tumour necrosis factor alpha (TNF-α) resulting in an increased 
likelihood of cell death[16]. ROS increases and activates c-Jun N-terminal kinase (JNK) 
with consecutive expression of the activator protein 1 (AP-1) transcription factor 
leading to cellular hyper-regeneration, and lipid peroxidation. Lipid peroxidation 
products such as malondialdehyde and HNE are generated. HNE can bind to 
adenosine and cytosine forming highly carcinogenic exocyclic etheno DNA adducts[17]. 
These DNA adducts have been identified in the livers of patients with ALD and other 
types of liver disease associated with inflammation and oxidative stress like viral 
hepatitis[18].
The other two most prevalent DNA adducts are N2-ethyldeoxyguanosine (N2-Et-
dG), and 1,N(2)-propano-2′-deoxyguanosine (PdG). N2-Et-dG is detectable in livers of 
alcohol-exposed mice and leukocytes of human alcohol misusers[19]. PdG, on the other 
hand, is distinguished by its genotoxic and mutagenic effects which impair DNA 
replication, thereby triggering cell death. These two major acetaldehyde-DNA adducts 
also promote carcinogenesis by initiating replication errors and mutations in 
oncogenes/onco-suppressor genes[19].
A third minor pathway for ethanol metabolism involves catalase, a peroxisomal 
enzyme (Figure 1)[20], which requires the presence of H2O2, a breakdown product of 
fatty acids. Catalase located in the peroxisomes of the hepatocyte plays only a minimal 
role in alcohol metabolism due to low hepatic production of H2O2. Under normal 
conditions, ADH metabolizes about 75%-80% of the ethanol entering the liver and 
MEOS the remainder. Hepatic ADH and hepatic catalase activities remain unchanged 
following chronic alcohol consumption, whereas hepatic MEOS activity strikingly 
increases and is responsible for the enhanced alcohol metabolism found after chronic 
alcohol consumption[11,12].
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Figure 1  The three major pathways of alcohol metabolism. The primary pathway is initiated by alcohol dehydrogenase, a NAD+ requiring enzyme 
expressed at high levels in hepatocytes, which oxidizes ethanol to acetaldehyde. The second major pathway, the microsomal ethanol oxidizing system pathway, 
involves the NADPH-requiring enzyme cytochrome P450 enzyme 2E1, which is induced by chronic alcohol exposure. The third pathway for ethanol metabolism is 
carried out by catalase, a peroxisomal enzyme. ADH: Alcohol dehydrogenase; ALDH2: Aldehyde dehydrogenase; CYP2E1: Cytochrome P450 enzyme 2E1; HNE: 4-
hydroxy-2-nonenal; LOOH: Lipid hydroperoxides; MDA: Malondialdehyde; MEOS: Microsomal ethanol oxidizing system; ROS: Reactive oxygen species.
MITOCHONDRIAL STRESS
Chronic alcohol consumption results in structural and functional abnormalities in 
hepatic mitochondria, including enlarged morphology[21,22], mitochondrial DNA 
(mtDNA) damage[23], reductions in hepatic ATP levels[24] and mitochondrial protein 
synthesis[25] (Figure 2). This can result in hepatocellular apoptosis and associated 
necrosis[26]. Chronic alcohol metabolism and associated mitochondrial dysfunction has 
been implicated in increasing ROS production and accumulation in hepatic 
mitochondria.
In humans, in vivo measurement of ROS is complicated due to their rapid reactions 
with surrounding molecules[27]. Surrogate measures of mitochondrial-derived ROS 
include urinary isoprostane levels[28,29], NADH delivery to the respiratory chain[30], lipid 
peroxidation[31,32] and HNE levels and associated adducts[17,33]. The greatest indicator of 
ROS overproduction is the increase in hepatic CYP2E1 levels[32,34-37]. The respiratory 
chain has also been implicated in mitochondrial ROS overproduction in response to 
chronic alcohol consumption. Excessive levels of reducing equivalents (e.g., NADH), 
produced by alcohol and ADH entering the mitochondrial respiratory chain, lead to 
electron transport chain reduction, facilitating superoxide anion formation[38,25].
Cell death can be triggered through ROS-induced release of apoptosis signal-
regulating kinase 1 (ASK1) (a member of the mitogen-activated protein kinase [MAPK] 
family), resulting in the cleavage of pro-caspase-3 to active caspase-3, which promotes 
cellular apoptosis[39-41]. Additionally, cytosolic ASK1 activates MAPK kinase 4 and JNK 
resulting in increased mitochondrial permeability, mediated by SAB protein, and thus 
hepatocyte cell death[40,41](Figure 2).
Reactive nitrogen species (RNS) also contribute to mitochondrial damage[22,38]. 
Alcohol-mediated overproduction of the superoxide anion can result in the generation 
of RNS, such as peroxynitrite, via interaction with nitric oxide, culminating in 
mitochondrial protein damage[25]. Numerous mitochondrial-localized enzymes 
involved in respiration and cellular energetic processes are inactivated in this way, 
including NADH dehydrogenase, succinate dehydrogenase, cytochrome c reductase 
and ATP synthase[42].
To limit oxidative damage following alcohol consumption, hepatic mitochondria 
have various adaptive mechanisms to prevent functional and structural impairments. 
Uncoupling proteins (UCPs), specifically UCPs 1-3, reduce ROS production by the 
uncoupling of mitochondrial oxidative phosphorylation[43], a process observed in 
patients with non-alcoholic fatty liver disease (NAFLD)[44]. Furthermore, there is 
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Figure 2  Pathways involved in mediating mitochondrial oxidative stress. Alcohol elevates mitochondrial cytochrome p450 2E1 and NADH levels 
facilitating reactive oxygen species (ROS) upregulation. Elevated ROS damages mitochondrial DNA, proteins and cristae and causes a reduction in mitochondrial 
ATP and glutathione. ROS-activated thioredoxin-interacting protein translocates to mitochondria binding thioredoxin 2, indirectly producing further ROS through 
inhibiting its antioxidant activity. Apoptosis signal-regulating kinase 1 liberated from thioredoxin 2, facilitates cleavage of pro-caspase 3 to caspase 3 leading to 
hepatocellular apoptosis. Mitochondrial ROS activates cytosolic apoptosis signal-regulating kinase 1 leading to downstream opening of the mitochondrial transition 
pore through mitogen-activated protein kinase kinase 4 and c-Jun N-terminal kinase activation. ROS form reactive nitrogen species which inhibit mitochondrial 
enzymes. ASK1: Apoptosis signal-regulating kinase 1; BAX: Bcl-2-associated X protein; CYP2E1: Cytochrome p450 2E1; ETC: Electron transport chain; GSH: 
Glutathione; JNK: C-Jun N-terminal kinase; MKK4: Mitogen-activated protein kinase kinase 4; mtDNA: Mitochondrial DNA; ROS: Reactive oxygen species; RNS: 
Reactive nitrogen species; SAB: SH3 domain-binding protein that preferentially associates with Btk; TRX2: Thioredoxin 2; TXNIP: Thioredoxin-interacting protein.
mitochondrial upregulation of enzymatic antioxidants catalase, glutathione transferase 
and heme oxygenase-1 and a marked increase in GSH[45,46]. However, mitochondrial 
GSH depletion was observed in patients with alcohol dependence and ALD[15,16] 
suggesting that chronic alcohol exposure downregulates GSH expression.
Manganese-dependent superoxide dismutase (MnSOD) detoxifies mitochondrial 
superoxide[47], but its response to alcohol is poorly documented. Increased 
mitochondrial localization of MnSOD was associated with more severe forms of 
ALD[48], which may be mediated by increased hydroxyl radical generation[22]. Thus, 
overexpression of MnSOD may be hepatotoxic rather than hepatoprotective.
S-adenosylmethionine (SAMe) has been implicated in regulating mitochondrial 
function, following alcohol consumption in a variety of animal models[49]. SAMe binds 
and inactivates the catalytic activity of CYP2E1[50], limiting alcohol-dependent 
increases in mitochondrial production of superoxide[49]. SAMe also increases synthesis 
and availability of glutathione[51] and maintains mitochondrial respiration rate and 
mtDNA integrity[38]. Although greater SAMe levels have been observed in the serum of 
ALD patients compared to healthy subjects[52], a reduction in hepatic SAMe levels was 
observed in patients with AH[53], suggesting the acute inflammatory state leads to 
hepatic SAMe depletion. SAMe has been evaluated as a treatment for AH in a recent 
phase 2 randomized controlled clinical trial. SAMe with prednisolone improved 6-mo 
survival compared to prednisolone treatment alone[54]. Although these preliminary 
results are encouraging, a definitive study has yet to be undertaken.
CELL SIGNALING PATHWAYS
Lipopolysaccharide (LPS) plays a key role in the pathogenesis of ALD, with higher 
circulating LPS levels in alcohol dependent patients[55,56]. In AH, LPS predicts organ 
failure, mortality[57] and infection[58]. Alcohol exposure increases gut permeability, 
mediating translocation of LPS from the lumen of the intestine to the portal vein into 
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the liver[55]. LPS binds to Toll-like receptor 4 (TLR4) expressed on a wide variety of 
immune and parenchymal cells including Kupffer cells, hepatocytes, endothelial cells 
and hepatic stellate cells, initiating one of the primary signaling cascades associated 
with liver damage[59,60]. LPS-mediated cell signaling results in transcription of pro-
inflammatory genes through nuclear factor-κB (NF-κB) and interferon regulatory 
factor 3 DNA binding[59,61].
Upon LPS stimulation of the TLR4 complex, NADPH oxidase (NOX) 4 interacts 
with the COOH-terminal region of TLR4 resulting in ROS generation in neutrophils 
and monocytes[62,63], which directly activates NF-κB[62,64]. ROS-mediated activation and 
potential regulation of NF-κB activity occurs by several mechanisms: IκBα 
phosphorylation; S-glutathionylation of IKKβ; disruption of IκB ubiquitination and 
degradation; NF-κB inducing kinase (NIK) activation and phosphoinositide 3-kinase 
(PI3K)/protein kinase B (Akt) stimulation[65] (Figure 3). ROS both negatively and 
positively regulates NF-κB, with oxidative stress in the early phase being a positive 
regulator, compared to a negative regulator in the late phase[66]. Diphenyliodonium 
(DPI), an inhibitor of NOX, used as a pre-treatment in alcohol-fed rats, results in 
normalized ROS production, and inhibition of TNF-α production in Kupffer cells[59,67]. 
Treatment of alcohol-fed rats with the antioxidant dilinoleoyl-phosphatidylcholine, 
also inhibited TNF-α production in Kupffer cells and LPS-induced NF-κB activation[68].
Diphenyliodonium and dilinoleoyl-phosphatidylcholine reduce extracellular signal-
regulated protein kinase (ERK)1/2 activation[67,68]. LPS-induced activation of ERK1/2 
results in transcription of early growth response protein 1 (Egr-1), involved in binding 
to the TNF-α promoter and increasing TNF-α expression[59]. Egr-1 deficient mice are 
protected from chronic alcohol-induced liver injury in association with decreased 
TNF-α messenger RNA (mRNA) levels[69].
LPS activates other MAPKs including p38 and JNK[59], involved in TNF-α 
production[70]. p38 has been implicated in maintaining the stability of TNF-α 
mRNA[59,71]. In response to acute alcohol exposure, the JNK pathway has been 
associated with increased hepatic mitochondrial ROS production[72], increased JNK 
phosphorylation and AP-1 binding in monocytes[73]. ROS is likely to activate JNK 
through interaction with upstream MEKK1[65] and by inactivating JNK inhibitor dual 
specificity protein phosphatase 1[40,74]. ROS have also been associated with activation of 
cytosolic ASK1[40] (Figure 3). Clinical trials of ASK1 inhibitors as a treatment for 
inflammatory liver disease are ongoing with a suggestion of reduced fibrosis in 
patients with NAFLD[75] but no efficacy seen in AH[76].
ROS-mediated S-glutathionylation results in decreased expression of downstream 
antioxidants such as MnSOD, catalase and Sestrin3 via the PI3K/AKT pathway[77]. Akt 
has also been implicated in increasing oxygen consumption, resulting in elevated 
mitochondrial generation of H2O2, facilitating further oxidative damage[78,79].
The net result of these alcohol-induced cell signaling pathways is the increased 
production of pro-inflammatory cytokines through upregulation of transcription 
factors such as AP-1 and NFκB. TNF-α, a key pro-inflammatory cytokine, is highly 
elevated in patients with ALD and AH[80-82], with observed TNF-α gene expression 
increasing in ALD patients[83]. TNF-α induces apoptosis through interaction with TNF-
α receptor 1 (TNFR1), initiating a cell-death cascade via activation of caspases[84]. In 
ALD, TNF-α-induces mitochondrial peroxidation[55], which is worsened following 
depletion of GSH[15,85].
TNF-α exacerbates oxidative damage and inflammation via a positive feedback loop. 
Through association with TNFR1, TNF-α stimulates the association of complex I[86], 
which culminates in MAPK activation (JNK, p38 and ERK). Complex I also directly 
contributes to ROS accumulation through generation of superoxide, capable of causing 
further oxidative damage and eventual TNF-α, perpetuating the cycle[40,87,88].
Soluble inflammatory mediators including interleukins have been implicated in 
ALD[60,89,90] and are associated with outcome in patients with AH[91]. Elevated serum IL-
6 levels have recently been identified as a predictor of mortality in severe AH 
patients[64]. Hepatic upregulation of IL-6 and IL-1β in ALD, results in the 
differentiation of naïve CD4+ cells into IL-17-producing T-helper 17 cells (Th17) 
(Figure 4), resulting in elevated hepatic and serum levels of IL-17 observed in ALD 
patients[64,92]. IL-17 has a multitude of pro-inflammatory downstream effects, including 
inducing neutrophil recruitment to the liver; stimulating IL-8 and CXCL1 production 
by hepatic stellate cells[93] and CXCL4, 5 and 6 expression[92,93]. IL-6 and interferon 
(IFN)-γ are involved in JAK/STAT activation promoting hepatic regeneration[59,94]. 
Conversely, despite upregulation of IL-6 in ALD patients, downregulation of STAT 
activation has been observed in human monocytes with chronic alcohol exposure[95].
Inflammasomes propagate IL-1β and IL-18 signals, important in the regulation of 
hepatic inflammation[94]. ROS mediates IL-1β and IL-18 signaling via inflammasome 
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Figure 3  Signaling pathways involved in exacerbating oxidative damage and liver injury. Lipopolysaccharide, alcohol and extracellular reactive 
oxygen species (ROS) are all capable of activating toll-like receptor 4 leading to myeloid differentiation primary response 88 (MyD88) activation. MyD88 association 
with interleukin-1 receptor-associated kinase 1-4 results in activation of the tumor necrosis factor receptor-associated factor 6/transforming growth factor beta-
activated kinase 1 complex, which activates MAPKs c-Jun N-terminal kinase, p38 and extracellular signal-regulated protein kinase, facilitating transcription factors 
activator protein 1 and early growth response protein 1 to translocate to the nucleus and upregulate pro-inflammatory mediators. Tumor necrosis factor receptor-
associated factor 6/transforming growth factor beta-activated kinase 1-mediated phosphorylation of the IKKα-β-γ complex leads to IκB phosphorylation and nuclear 
factor κB (NF-κB) translocation to the nucleus to upregulate pro-inflammatory cytokines. MyD88 signaling also activates NADPH oxidase 4 to produces ROS. ROS 
are also produced by the NADPH oxidase 1/ras-related C3 botulinum toxin substrate 1 complex which is activated upstream by tumour necrosis factor alpha 
interacting with tumour necrosis factor alpha receptor type 1, at the cell surface, which activates complex I. ROS upregulate NF-κB translocation to the nucleus 
through IκB phosphorylation, nuclear factor κB inducing kinase activation and indirect protein kinase B activation. At high concentrations, ROS inhibit NF-κB 
activation through inhibition of IκB phosphorylation and S-glutathionylation of IKKβ. ROS inhibit dual specificity protein phosphatase 1 and thioredoxin to further 
upregulate the c-Jun N-terminal kinase pathway. ROS inactivation of phosphatase and tensin homolog facilitates phosphoinositide 3-kinase to produce protein kinase 
B, which elevates ROS levels via increased oxygen consumption, and inactivates forkhead box protein O and downstream antioxidant expression. AKT: Protein 
kinase B; AP-1: Activator protein 1; ASK1: Apoptosis signal-regulating kinase 1; DUSP1: Dual specificity protein phosphatase 1; Egr-1: Early growth response protein 
1; ERK: Extracellular signal-regulated protein kinase; FOXO: Forkhead box protein O; IAP: Inhibitor of apoptosis; IFN: Interferon; IL: Interleukin; IRAK: Interleukin-1 
receptor-associated kinase 1; JNK: C-Jun N-terminal kinase; LPS: Lipopolysaccharide; MEKK1: Mitogen-activated protein kinase kinase kinase 1; MyD88: Myeloid 
differentiation primary response 88; NF-κB: Nuclear factor κB; NIK: Nuclear factor κB inducing kinase; NOX: NADPH oxidase; MnSOD: Manganese-dependent 
superoxide dismutase; PI3K: Phosphoinositide 3-kinase; PTEN: Phosphatase and tensin homolog; Rac1: Ras-related C3 botulinum toxin substrate 1; ROS: Reactive 
oxygen species; TAK1: Transforming growth factor beta-activated kinase 1; TLR4: Toll-like receptor 4; TNF-α: Tumour necrosis factor alpha; TNFR1: Tumour 
necrosis factor alpha receptor 1; TRADD: Tumour necrosis factor alpha receptor 1-associated death domain protein; TRAF: Tumor necrosis factor receptor-
associated factor; TRIF: TIR-domain-containing adapter-inducing interferon-β; TRX: Thioredoxin; TXNIP: Thioredoxin-interacting protein.
NLRP3 activation[96,97] and inhibition of antioxidant molecules[41] (Figure 4). Increased 
production of IL-1β is critical in Th17 differentiation[64,92,98], while IL-18 activates natural 
killer T-cells (NKTs) to produce IFN-γ[99]. Anti-IL-18 antibodies reduce activation of 
NF-κB and AP-1, inflammation, liver damage and mortality in animal models[99,100]. IL-
1β has also been identified as an activator of MAPKs, including p38, JNK, MEKK1 and 
IKKβ, involved in mediating upregulation of itself and other pro-inflammatory 
cytokines[101], creating another positive feedback loop.
TRACE ELEMENTS
Trace elements are a group of naturally occurring minerals that are nutritionally 
fundamental to basic cellular and immunological functions[102]. An essential role of the 
these molecules, including zinc, copper, selenium and manganese, is to act as cofactors 
of anti-oxidant enzymes, making their role imperative in the context of oxidative 
stress[103,104]. Manganese, copper and zinc are part of the SOD enzyme group that 
catalyze the breakdown of highly reactive superoxide radicals to H2O2 or O2-. Selenium 
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Figure 4  Nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3 inflammasome activation and 
downstream signaling. Reactive oxygen species (ROS) activate thioredoxin-interacting protein via inhibition of oxidoreductase thioredoxin. Thioredoxin-
interacting protein both binds and activates nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3 inflammasomes and interacts with 
thioredoxin 1 and 2 to indirectly promote further ROS generation through inhibiting their antioxidant activity. Activated nucleotide-binding domain, leucine-rich-
containing family, pyrin domain-containing-3 inflammasomes facilitate pro-caspase 1 cleavage to caspase 1, which facilitates pro- interleukin (IL)-1β and pro-IL-18 
cleavage to IL-1β and IL-18 respectively. IL-18 induces interferon-γ production by natural killer T-cells. IL-1β induces generation of T-helper 17 cells in addition to 
nuclear factor κB and activator protein 1 activation through IKKβ, p38, c-Jun N-terminal kinase and mitogen-activated protein kinase kinase kinase 1 stimulation. 
Activating nuclear factor κB and activator protein 1 results in pro-inflammatory cytokine release, indirectly inducing further ROS accumulation. AP-1: Activator protein 
1; IFN: Interferon; IL: Interleukin; JNK: C-Jun N-terminal kinase; MEKK1: Mitogen-activated protein kinase kinase kinase 1; NF-κB: Nuclear factor κB; NKT: Natural 
killer T-cell; NLRP3: Nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3; NOX: NADPH oxidase; Rac1: Ras-related C3 botulinum 
toxin substrate 1; ROS: Reactive oxygen species; Th17: T-helper 17 cells; TNF-α: Tumour necrosis factor alpha; TNFR1: Tumour necrosis factor alpha receptor 1; 
TRX: Thioredoxin; TXNIP: Thioredoxin-interacting protein.
is a component of the active site of glutathione peroxides (GPx), the main function of 
which is the neutralization of hydrogen peroxide[105]. These enzyme systems are crucial 
in counterbalancing the oxidative stress state and are impaired in chronic liver 
disease[106].
Reduced serum levels of trace elements have been confirmed in patients with liver 
disease, including ALD, and correlate with severity[107-110]. Decreased zinc is associated 
with liver cirrhosis in alcohol dependent individuals[111] and reduced serum levels of 
zinc, copper and iron have been observed when compared with healthy controls[112]. 
Zinc is a crucial trace element involved in multiple cellular and metabolic pathways[113] 
as well as acting as a cofactor for ALDH. Deficiency or abnormality in zinc function is 
implicated multiple pathologies, including liver disease (both acute and chronic)[114,115] 
and is associated with immune dysfunction evidenced by increased inflammation and 
aberrant immune cell activation[116]. Zinc deficiency in endothelial cells results in 
increased oxidative stress and decreased inflammatory regulation which is corrected 
or partially ameliorated by zinc supplementation[117,118]. In alcohol-fed mice, zinc 
deficiency worsens the balance between hepatic pro- and antioxidant enzymes[119] and 
is associated with accumulation of ROS in gut epithelial cells and disruption of tight 
junctions[120]. Given zinc’s influence on antioxidant responses, gut integrity and 
immune function, a trial of zinc supplementation to improve clinical outcomes in 
patients with ALD cirrhosis is ongoing (NCT02072746). Preliminary reports suggest 
zinc supplementation is associated with a reduction in liver inflammation and 
improvement in immune function[121].
Antioxidant therapy may also have a benefit in the treatment of AH. An antioxidant 
cocktail (including zinc and selenium) in combination with steroids for the treatment 
of severe AH correlated with a significant reduction in serum biomarkers, improved 
short-term prognosis and reduced length of stay in hospital[122]. However, a subsequent 
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study of a complex regimen of N-acetylcysteine (NAC) followed by antioxidant 
therapy, alone or in conjunction with steroids, reduced renal injury but resulted in no 
survival benefit over 6 mo[121]. Another clinical trial of steroids combined with NAC in 
AH showed reduced infection rate but not mortality at 6 mo[123]. Antioxidants have also 
been shown to have a protective effect in patients with NAFLD by reducing serum 
levels of alanine transaminase (ALT) and spleen size, a finding that likely correlates 
with an improvement of fatty infiltration[122]. These findings suggest that targeting or 
counterbalancing oxidative stress in ALD patients may improve patient outcomes.
EPIGENETICS
Lifestyle and environmental factors can modify gene expression without altering the 
DNA sequence, which gets transmitted to the next generation of cells after mitotic 
division, termed epigenetics[123]. Epigenetic regulation includes both DNA and histone 
protein modifications as well as action through non-coding micro RNAs[123]. DNA 
methylation is the most abundant epigenetic modification that directly affects the 
function of a gene in eukaryotes[124]. Acetylation and deacetylation are modifications in 
histone proteins carried out by two enzyme families, histone deacetylases (HDACs) 
and histone acetyl transferase (HAT)[124]. Histone modifying enzymes contribute to the 
activation or inactivation of transcription by catalyzing the unfolding or further 
compaction, respectively, of chromatin structure[124].
Excessive ROS is involved in epigenetic gene activation or silencing by changing 
DNA methylation levels[125]. ROS production induces alterations in DNA methylation 
patterns and global histone acetylation, which then lead to aberrant gene expression, 
and may contribute to the process of carcinogenesis[124]. The reduction of global histone 
acetylation in short term oxidative stress might be due to an immediate increase of 
class I/II HDAC activity by an unknown mechanism[126,127]. Class III HDAC (Sirtuin 
NAD+-dependent family of protein deacetylases) has been hypothesized to be 
upregulated under oxidative stress because NAD+ levels increase in the mitochondria 
under oxidative stress conditions but direct evidence is lacking[126].
Alcohol consumption increases gene-selective acetylation of histone H3 at lysine 9 
(H3K9), levels of enzymes mediating histone acetylation, and results in a generalized 
increase in DNA methylation[126,127]. These epigenetic-mediated effects of alcohol 
consumption regulate the inflammatory response, through key pro-inflammatory 
cytokines, such as TNF-α, which is silenced by H3K9 methylation and activated by 
H3K9 acetylation[128]. In a macrophage cell line, alcohol treatment resulted in global 
increased histone H3 and H4 acetylation and specifically increased acetylation of pro-
inflammatory gene histones[129].
Oxidative stress itself is an important regulator of epigenetic processes by inhibition 
of HDAC expression[130]. This takes place via activation of PI3Kδ, a signalling molecule 
controlling many inflammatory signalling pathways[131]. Drugs that inhibit PI3Kδ (e.g., 
theophylline, nortriptyline and specific inhibitors) reduce oxidative stress in in vitro 
and in vivo models of lung disease[132]. In patients with AH, there is in vitro evidence 
that theophylline can enhance response to corticosteroid treatment, which may be 
mediated by its epigenetic effects[133]. Targeting epigenetic regulation has recently been 
shown to have a beneficial effect in patients with AH; a novel sulphated oxysterol, 
DUR-928, was well tolerated and improved liver biochemistry in a small phase 2 
clinical trial in AH[134].
Activation of the transcription factor Nrf2 is central to cellular defence against 
ROS[135]. Its negative regulator, kelch-like ECM-associated protein 1 (Keap1), promotes 
proteasomal degradation of Nrf2. ROS decouples Nrf2 from Keap1, allowing it to 
translocate to the nucleus to bind to antioxidant response elements (AREs), initiating a 
range of antioxidant processes[135,136]. Both Nrf2 and Keap1 expression are influenced by 
epigenetics with evidence of DNA hypermethylation in the Nrf2 promoter[135,136] and 
Keap1 promoter[137]. Histone acetylation and deacetylation also modify ARE-
dependent gene expression with Class 1 HDACs reducing Nrf2[138]. Conversely, HDAC 
inhibitors restore Nrf2 expression and antioxidant responses. Targeting epigenetic 
regulation of Nrf2/Keap1 to ameliorate oxidative stress induced inhibition of 
antioxidant responses is an appealing strategy[138]. However, much of this work has 
been performed in cancer cell lines and needs further investigation in the context of 
ALD.
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IMPLICATIONS FOR THERAPY OF ALD
An improved understanding of the detailed mechanisms by which oxidative stress 
influences liver damage in patients with ALD may yield new targets for therapy. 
Current data from pre-clinical and clinical studies suggest potential new avenues for 
therapy of ALD.
MITOCHONDRIAL STRESS
Chronic alcohol consumption results in significant mitochondrial ROS generation 
leading to morphological and functional changes. Preventing ROS generation may 
ameliorate this process. Pre-clinical and early phase clinical studies have shown 
promise of this approach with SAMe. A systematic review and meta-analysis of 11 
randomized controlled trials of SAMe treatment for chronic liver disease concluded 
that it improved liver biochemistry (bilirubin and AST) and had a good safety profile 
but did not affect mortality[139]. Long term SAMe treatment in patients with ALD does 
not appear to be clinically effective with no reduction in adverse events or mortality in 
the two included studies performed in patients with ALD[140,141]. However, short term 
treatment of the acute mitochondrial stress seen in AH may be a better strategy for the 
use of SAMe. A phase 2 clinical trial of SAMe with prednisolone for the treatment of 
severe AH demonstrated improved response rate measured by Lille score and a 
reduction in hepatorenal syndrome[54]. However, there was no statistically significant 
difference in 28-d mortality. It may yet prove to be an effective adjunct to anti-
inflammatory therapy for AH.
UCPs are strongly associated with mitochondrial stress in ALD. Overexpression of 
UCP2 reduces apoptosis and oxidative stress in vitro[142]. Hepatocellular downregulated 
mitochondrial carrier protein (HDMCP) expression induced uncoupling and reduced 
steatosis in an animal model of NAFLD[143]. However, such an approach may promote 
hepatocyte necrosis and increase the risk of hepatocellular carcinoma[144]. Further 
studies in this area are required to determine whether targeting UCPs would be a 
beneficial therapeutic strategy.
ANTIOXIDANT THERAPY
NAC, an antioxidant therapy that provides cysteine for glutathione synthesis, has been 
tested in patients with AH. Although initial trials did not demonstrate a survival 
benefit[145,146]. a more recent study of NAC in combination with prednisolone, showed a 
reduction in infective events and 1-month mortality[147]. Therefore, NAC has been 
suggested for the treatment of AH in clinical practice guidelines, with the caveat that a 
definitive randomized controlled trial is still required[148].
Deficiency of key trace elements is associated with oxidative stress, which is 
ameliorated by supplementation. Antioxidant therapy including zinc and other trace 
elements has shown clinical benefit in patients with AH[122]. However, interpretation is 
hampered by use of a variety of antioxidants at differing concentrations and 
durations[145,146]. A trial of long-term zinc supplementation in ALD patients has 
demonstrated improvements in short-term immune function[149] with long-term clinical 
outcomes due to be reported shortly. Improved understanding of the role of trace 
elements in ALD and the optimal formulation and duration of treatment is required.
EPIGENETIC REGULATION
Oxidative stress reduces HDAC expression via PI3Kδ activation resulting in increased 
expression of pro-inflammatory genes. Studies targeting HDACs have yet to be 
performed in patients with ALD. Although in vitro studies suggest an antioxidant 
effect of HDAC inhibition with upregulation of Nrf2 expression[138], HDAC inhibitors 
approved for use in the treatment of cancer induce cell cycle arrest, apoptosis and 
oxidative stress in cancer cells which overexpress HDAC[150]. The effect of HDAC 
inhibitors in the context of ALD requires careful in vitro confirmation before clinical 
translation. However, targeting PI3Kδ is a more appealing strategy with evidence 
from the respiratory field that specific inhibitors reduce oxidative stress in vitro and in 
vivo[132].
Tan HK et al. Oxidative stress in ALD
WJH https://www.wjgnet.com 342 July 27, 2020 Volume 12 Issue 7
CONCLUSION
Alcohol is a major global healthcare and economic burden and is a growing cause of 
chronic liver disease. However, there are currently no effective therapies to treat ALD. 
Oxidative stress is involved in multiple aspects of ALD pathogenesis (Figure 5). 
Chronic alcohol consumption results in the saturation of the ADH pathway and 
increased CYP2E1-mediated alcohol metabolism. This leads to the generation of 
reactive species including MAA, HNE, lipid hydroperoxides, RNS and ROS, which 
cause hepatic damage via lipid and protein peroxidation, adduct formation and 
cellular hyper-regulation. Similar damage occurs in hepatic mitochondria with ROS 
inducing structural and functional damage. ROS cause oxidative damage through 
multiple mechanisms: Promoting cell death via protein mediators, increasing and 
sustaining the upregulation of pro-inflammatory mediators, as well as inducing 
multiple epigenetic modifications.
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Figure 5  Reactive oxygen species-mediated oxidative damage in the liver. Increased cytochrome p450 2E1-mediated alcohol breakdown and electron 
transport chain reduction results in overproduction of reactive oxygen species (ROS). Excess alcohol causes gut hyperpermeability resulting in tight junction 
disruption and an excess of lipopolysaccharide translocation from the gut to the liver. Lipopolysaccharide activates NADPH oxidase via toll-like receptor 4 activation 
resulting in further ROS production. Excess ROS produce RNS and reduce antioxidant cofactors such as Mn and Zn. ROS induce hepatocyte damage through 
activation of apoptosis signal-regulating kinase 1. Nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3 inflammasomes are activated 
by ROS, inducing T-helper 17 generation and natural killer T cell-mediated interferon-γ production through interleukin expression. ROS upregulate transcription 
factors activator protein 1 and nuclear factor κB resulting in pro-inflammatory cytokine expression causing downstream liver inflammation. Tumour necrosis factor 
alpha further upregulates ROS through activating NADPH oxidase via tumour necrosis factor alpha receptor 1. ROS cause an array of functional and structural 
mitochondrial damage, which is initially impeded by uncoupling proteins and SAMe expression. ROS mediates epigenetic alterations through interacting with HDACs 
which mediate histone acetylation. Ac: Acetylation; ADH: Alcohol dehydrogenase; AP-1: Activator protein 1; ASK1: Apoptosis signal-regulating kinase 1; Cu: Copper; 
CYP2E1: Cytochrome p450 2E1; ETC: Electron transport chain; HDAC: Histone deacetylases; IFN: Interferon; IL: Interleukin; LPS: Lipopolysaccharide; Mn: 
Manganese; NF-κB: Nuclear factor κB; NKT: Natural killer T-cell; NOX: NADPH oxidase; ROS: Reactive oxygen species; SAMe: S-adenosylmethionine; Se: 
Selenium; Th17: T-helper 17 cells; TLR4: Toll-like receptor 4; TNF-α: Tumour necrosis factor alpha; TNFR1: Tumour necrosis factor alpha receptor 1; UCP: 
Uncoupling protein; Zn: Zinc.
REFERENCES
1 Pimpin L, Cortez-Pinto H, Negro F, Corbould E, Lazarus JV, Webber L, Sheron N; EASL HEPAHEALTH 
Steering Committee. Burden of liver disease in Europe: Epidemiology and analysis of risk factors to identify 
prevention policies. J Hepatol 2018; 69: 718-735 [PMID: 29777749 DOI: 10.1016/j.jhep.2018.05.011]
2 Bhattacharya A. Which cost of alcohol? What should we compare it against? Addiction 2017; 112: 559-
565 [PMID: 26970215 DOI: 10.1111/add.13335]
3 Anderson P, Baumberg B. Alcohol in Europe-Public Health Perspective: Report summary. Drugs Educ 
Prev Policy 2006; 13: 483-488 [DOI: 10.1080/09687630600902477]
4 Ohashi K, Pimienta M, Seki E. Alcoholic liver disease: A current molecular and clinical perspective. Liver 
Res 2018; 2: 161-172 [PMID: 31214376 DOI: 10.1016/j.livres.2018.11.002]
5 Philips CA, Augustine P, Yerol PK, Rajesh S, Mahadevan P. Severe alcoholic hepatitis: current 
perspectives. Hepat Med 2019; 11: 97-108 [PMID: 31496843 DOI: 10.2147/HMER.S197933]
6 Bennett K, Enki DG, Thursz M, Cramp ME, Dhanda AD. Systematic review with meta-analysis: high 
mortality in patients with non-severe alcoholic hepatitis. Aliment Pharmacol Ther 2019; 50: 249-257 
[PMID: 31231848 DOI: 10.1111/apt.15376]
7 Li S, Tan HY, Wang N, Zhang ZJ, Lao L, Wong CW, Feng Y. The Role of Oxidative Stress and 
Antioxidants in Liver Diseases. Int J Mol Sci 2015; 16: 26087-26124 [PMID: 26540040 DOI: 
10.3390/ijms161125942]
8 Cederbaum AI, Lu Y, Wu D. Role of oxidative stress in alcohol-induced liver injury. Arch Toxicol 2009; 
83: 519-548 [PMID: 19448996 DOI: 10.1007/s00204-009-0432-0]
9 Willis MS, Klassen LW, Tuma DJ, Sorrell MF, Thiele GM. Adduction of soluble proteins with 
malondialdehyde-acetaldehyde (MAA) induces antibody production and enhances T-cell proliferation. 
Alcohol Clin Exp Res 2002; 26: 94-106 [PMID: 11821659 DOI: 10.1111/j.1530-0277.2002.tb02436.x]
Lieber CS, Rubin E, DeCarli LM. Hepatic microsomal ethanol oxidizing system (MEOS): differentiation 
from alcohol dehydrogenase and NADPH oxidase. Biochem Biophys Res Commun 1970; 40: 858-865 
[PMID: 4395603 DOI: 
10
Tan HK et al. Oxidative stress in ALD
WJH https://www.wjgnet.com 344 July 27, 2020 Volume 12 Issue 7
10.1016/0006-291X(70)90982-4]
11 Pérez MJ, Cederbaum AI. Metallothionein 2A induction by zinc protects HEPG2 cells against CYP2E1-
dependent toxicity. Free Radic Biol Med 2003; 34: 443-455 [PMID: 12566070 DOI: 
10.1016/S0891-5849(02)01302-3]
12 Weltman MD, Farrell GC, Hall P, Ingelman-Sundberg M, Liddle C. Hepatic cytochrome P450 2E1 is 
increased in patients with nonalcoholic steatohepatitis. Hepatology 1998; 27: 128-133 [PMID: 9425928 
DOI: 10.1002/hep.510270121]
13 Lieber CS, Seitz HK, Garro AJ, Worner TM. Alcohol-related diseases and carcinogenesis. Cancer Res 
1979; 39: 2863-2886 [PMID: 221110]
14 Seitz HK, Stickel F. Risk factors and mechanisms of hepatocarcinogenesis with special emphasis on alcohol 
and oxidative stress. Biol Chem 2006; 387: 349-360 [PMID: 16606331 DOI: 10.1515/BC.2006.047]
15 Albano E. Oxidative mechanisms in the pathogenesis of alcoholic liver disease. Mol Aspects Med 2008; 29: 
9-16 [PMID: 18045675 DOI: 10.1016/j.mam.2007.09.004]
16 Fernandez-Checa JC, Kaplowitz N. Hepatic mitochondrial glutathione: transport and role in disease and 
toxicity. Toxicol Appl Pharmacol 2005; 204: 263-273 [PMID: 15845418 DOI: 10.1016/j.taap.2004.10.001]
17 Setshedi M, Wands JR, Monte SM. Acetaldehyde adducts in alcoholic liver disease. Oxid Med Cell Longev 
2010; 3: 178-185 [PMID: 20716942 DOI: 10.4161/oxim.3.3.12288]
18 Nair J, Srivatanakul P, Haas C, Jedpiyawongse A, Khuhaprema T, Seitz HK, Bartsch H. High urinary 
excretion of lipid peroxidation-derived DNA damage in patients with cancer-prone liver diseases. Mutat Res 
2010; 683: 23-28 [PMID: 19822158 DOI: 10.1016/j.mrfmmm.2009.10.002]
19 Abdelmegeed MA, Choi Y, Ha SK, Song BJ. Cytochrome P450-2E1 promotes aging-related hepatic 
steatosis, apoptosis and fibrosis through increased nitroxidative stress. Free Radic Biol Med 2016; 91: 188-
202 [PMID: 26703967 DOI: 10.1016/j.freeradbiomed.2015.12.016]
20 Handler JA, Thurman RG. Hepatic ethanol metabolism is mediated predominantly by catalase-H2O2 in the 
fasted state. FEBS Lett 1988; 238: 139-141 [PMID: 3169246 DOI: 10.1016/0014-5793(88)80243-6]
21 Nassir F, Ibdah JA. Role of mitochondria in alcoholic liver disease. World J Gastroenterol 2014; 20: 2136-
2142 [PMID: 24605012 DOI: 10.3748/wjg.v20.i9.2136]
22 Das SK, Vasudevan DM. Alcohol-induced oxidative stress. Life Sci 2007; 81: 177-187 [PMID: 17570440 
DOI: 10.1016/j.lfs.2007.05.005]
23 Venkatraman A, Landar A, Davis AJ, Chamlee L, Sanderson T, Kim H, Page G, Pompilius M, Ballinger S, 
Darley-Usmar V, Bailey SM. Modification of the mitochondrial proteome in response to the stress of 
ethanol-dependent hepatotoxicity. J Biol Chem 2004; 279: 22092-22101 [PMID: 15033988 DOI: 
10.1074/jbc.M402245200]
24 Grattagliano I, Russmann S, Diogo C, Bonfrate L, Oliveira PJ, Wang DQ, Portincasa P. Mitochondria in 
chronic liver disease. Curr Drug Targets 2011; 12: 879-893 [PMID: 21269263 DOI: 
10.2174/138945011795528877]
25 García-Ruiz C, Kaplowitz N, Fernandez-Checa JC. Role of Mitochondria in Alcoholic Liver Disease. Curr 
Pathobiol Rep 2013; 1: 159-168 [PMID: 25343061 DOI: 10.1007/s40139-013-0021-z]
26 Hoek JB, Cahill A, Pastorino JG. Alcohol and mitochondria: a dysfunctional relationship. Gastroenterology 
2002; 122: 2049-2063 [PMID: 12055609 DOI: 10.1053/gast.2002.33613]
27 Beier JI, McClain CJ. Mechanisms and cell signaling in alcoholic liver disease. Biol Chem 2010; 391: 
1249-1264 [PMID: 20868231 DOI: 10.1515/BC.2010.137]
28 Meagher EA, Barry OP, Burke A, Lucey MR, Lawson JA, Rokach J, FitzGerald GA. Alcohol-induced 
generation of lipid peroxidation products in humans. J Clin Invest 1999; 104: 805-813 [PMID: 10491416 
DOI: 10.1172/JCI5584]
29 Morrow JD. The isoprostanes: their quantification as an index of oxidant stress status in vivo. Drug Metab 
Rev 2000; 32: 377-385 [PMID: 11139135 DOI: 10.1081/DMR-100102340]
30 Mantena SK, King AL, Andringa KK, Landar A, Darley-Usmar V, Bailey SM. Novel interactions of 
mitochondria and reactive oxygen/nitrogen species in alcohol mediated liver disease. World J Gastroenterol 
2007; 13: 4967-4973 [PMID: 17854139 DOI: 10.3748/wjg.v13.i37.4967]
31 Ekström G, Ingelman-Sundberg M. Rat liver microsomal NADPH-supported oxidase activity and lipid 
peroxidation dependent on ethanol-inducible cytochrome P-450 (P-450IIE1). Biochem Pharmacol 1989; 38: 
1313-1319 [PMID: 2495801 DOI: 10.1016/0006-2952(89)90338-9]
32 Seth D, Haber PS, Syn WK, Diehl AM, Day CP. Pathogenesis of alcohol-induced liver disease: classical 
concepts and recent advances. J Gastroenterol Hepatol 2011; 26: 1089-1105 [PMID: 21545524 DOI: 
10.1111/j.1440-1746.2011.06756.x]
33 Roede JR, Jones DP. Reactive species and mitochondrial dysfunction: mechanistic significance of 4-
hydroxynonenal. Environ Mol Mutagen 2010; 51: 380-390 [PMID: 20544880 DOI: 10.1002/em.20553]
34 Niemelä O, Parkkila S, Juvonen RO, Viitala K, Gelboin HV, Pasanen M. Cytochromes P450 2A6, 2E1, and 
3A and production of protein-aldehyde adducts in the liver of patients with alcoholic and non-alcoholic liver 
diseases. J Hepatol 2000; 33: 893-901 [PMID: 11131450 DOI: 10.1016/S0168-8278(00)80120-8]
35 Takahashi T, Lasker JM, Rosman AS, Lieber CS. Induction of cytochrome P-4502E1 in the human liver by 
ethanol is caused by a corresponding increase in encoding messenger RNA. Hepatology 1993; 17: 236-245 
[PMID: 8428720 DOI: 10.1002/hep.1840170213]
36 Yun JW, Son MJ, Abdelmegeed MA, Banerjee A, Morgan TR, Yoo SH, Song BJ. Binge alcohol promotes 
hypoxic liver injury through a CYP2E1-HIF-1α-dependent apoptosis pathway in mice and humans. Free 
Radic Biol Med 2014; 77: 183-194 [PMID: 25236742 DOI: 10.1016/j.freeradbiomed.2014.08.030]
37 Adam-Vizi V. Production of reactive oxygen species in brain mitochondria: contribution by electron 
transport chain and non-electron transport chain sources. Antioxid Redox Signal 2005; 7: 1140-1149 [PMID: 
16115017 DOI: 10.1089/ars.2005.7.1140]
38 Manzo-Avalos S, Saavedra-Molina A. Cellular and mitochondrial effects of alcohol consumption. Int J 
Environ Res Public Health 2010; 7: 4281-4304 [PMID: 21318009 DOI: 10.3390/ijerph7124281]
39 Harijith A, Ebenezer DL, Natarajan V. Reactive oxygen species at the crossroads of inflammasome and 
inflammation. Front Physiol 2014; 5: 352 [PMID: 25324778 DOI: 10.3389/fphys.2014.00352]
Tan HK et al. Oxidative stress in ALD
WJH https://www.wjgnet.com 345 July 27, 2020 Volume 12 Issue 7
40 Seki E, Brenner DA, Karin M. A liver full of JNK: signaling in regulation of cell function and disease 
pathogenesis, and clinical approaches. Gastroenterology 2012; 143: 307-320 [PMID: 22705006 DOI: 
10.1053/j.gastro.2012.06.004]
41 Gunawan BK, Liu ZX, Han D, Hanawa N, Gaarde WA, Kaplowitz N. c-Jun N-terminal kinase plays a 
major role in murine acetaminophen hepatotoxicity. Gastroenterology 2006; 131: 165-178 [PMID: 
16831600 DOI: 10.1053/j.gastro.2006.03.045]
42 Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev 2007; 
87: 315-424 [PMID: 17237348 DOI: 10.1152/physrev.00029.2006]
43 Mailloux RJ, Harper ME. Uncoupling proteins and the control of mitochondrial reactive oxygen species 
production. Free Radic Biol Med 2011; 51: 1106-1115 [PMID: 21762777 DOI: 
10.1016/j.freeradbiomed.2011.06.022]
44 Chavin KD, Yang S, Lin HZ, Chatham J, Chacko VP, Hoek JB, Walajtys-Rode E, Rashid A, Chen CH, 
Huang CC, Wu TC, Lane MD, Diehl AM. Obesity induces expression of uncoupling protein-2 in 
hepatocytes and promotes liver ATP depletion. J Biol Chem 1999; 274: 5692-5700 [PMID: 10026188 DOI: 
10.1074/jbc.274.9.5692]
45 Cederbaum AI. Cytochrome P450 2E1-dependent oxidant stress and upregulation of anti-oxidant defense 
in liver cells. J Gastroenterol Hepatol 2006; 21 Suppl 3: S22-S25 [PMID: 16958665 DOI: 
10.1111/j.1440-1746.2006.04595.x]
46 Marí M, Cederbaum AI. CYP2E1 overexpression in HepG2 cells induces glutathione synthesis by 
transcriptional activation of gamma-glutamylcysteine synthetase. J Biol Chem 2000; 275: 15563-15571 
[PMID: 10748080 DOI: 10.1074/jbc.M907022199]
47 Candas D, Li JJ. MnSOD in oxidative stress response-potential regulation via mitochondrial protein influx. 
Antioxid Redox Signal 2014; 20: 1599-1617 [PMID: 23581847 DOI: 10.1089/ars.2013.5305]
48 Degoul F, Sutton A, Mansouri A, Cepanec C, Degott C, Fromenty B, Beaugrand M, Valla D, Pessayre D. 
Homozygosity for alanine in the mitochondrial targeting sequence of superoxide dismutase and risk for 
severe alcoholic liver disease. Gastroenterology 2001; 120: 1468-1474 [PMID: 11313317 DOI: 
10.1053/gast.2001.24051]
49 Andringa KK, King AL, Eccleston HB, Mantena SK, Landar A, Jhala NC, Dickinson DA, Squadrito GL, 
Bailey SM. Analysis of the liver mitochondrial proteome in response to ethanol and S-adenosylmethionine 
treatments: novel molecular targets of disease and hepatoprotection. Am J Physiol Gastrointest Liver Physiol 
2010; 298: G732-G745 [PMID: 20150243 DOI: 10.1152/ajpgi.00332.2009]
50 Cederbaum AI. Hepatoprotective effects of S-adenosyl-L-methionine against alcohol- and cytochrome 
P450 2E1-induced liver injury. World J Gastroenterol 2010; 16: 1366-1376 [PMID: 20238404 DOI: 
10.3748/wjg.v16.i11.1366]
51 Fernández-Checa JC, Colell A, García-Ruiz C. S-Adenosyl-L-methionine and mitochondrial reduced 
glutathione depletion in alcoholic liver disease. Alcohol 2002; 27: 179-183 [PMID: 12163147 DOI: 
10.1016/S0741-8329(02)00229-X]
52 Mudd SH, Wagner C, Luka Z, Stabler SP, Allen RH, Schroer R, Wood T, Wang J, Wong LJ. Two patients 
with hepatic mtDNA depletion syndromes and marked elevations of S-adenosylmethionine and methionine. 
Mol Genet Metab 2012; 105: 228-236 [PMID: 22137549 DOI: 10.1016/j.ymgme.2011.11.006]
53 Lee TD, Sadda MR, Mendler MH, Bottiglieri T, Kanel G, Mato JM, Lu SC. Abnormal hepatic methionine 
and glutathione metabolism in patients with alcoholic hepatitis. Alcohol Clin Exp Res 2004; 28: 173-181 
[PMID: 14745316 DOI: 10.1097/01.ALC.0000108654.77178.03]
54 Tkachenko P, Maevskaya M, Pavlov A, Komkova I, Pavlov C, Ivashkin V. Prednisolone plus S-adenosil-
L-methionine in severe alcoholic hepatitis. Hepatol Int 2016; 10: 983-987 [PMID: 27337960 DOI: 
10.1007/s12072-016-9751-4]
55 Lucey MR, Mathurin P, Morgan TR. Alcoholic hepatitis. N Engl J Med 2009; 360: 2758-2769 [PMID: 
19553649 DOI: 10.1056/NEJMra0805786]
56 Fujimoto M, Uemura M, Nakatani Y, Tsujita S, Hoppo K, Tamagawa T, Kitano H, Kikukawa M, Ann T, 
Ishii Y, Kojima H, Sakurai S, Tanaka R, Namisaki T, Noguchi R, Higashino T, Kikuchi E, Nishimura K, 
Takaya A, Fukui H. Plasma endotoxin and serum cytokine levels in patients with alcoholic hepatitis: relation 
to severity of liver disturbance. Alcohol Clin Exp Res 2000; 24: 48S-54S [PMID: 10803780 DOI: 
10.1111/j.1530-0277.2000.tb00012.x]
57 Michelena J, Altamirano J, Abraldes JG, Affò S, Morales-Ibanez O, Sancho-Bru P, Dominguez M, García-
Pagán JC, Fernández J, Arroyo V, Ginès P, Louvet A, Mathurin P, Mehal WZ, Caballería J, Bataller R. 
Systemic inflammatory response and serum lipopolysaccharide levels predict multiple organ failure and 
death in alcoholic hepatitis. Hepatology 2015; 62: 762-772 [PMID: 25761863 DOI: 10.1002/hep.27779]
58 Vergis N, Atkinson SR, Knapp S, Maurice J, Allison M, Austin A, Forrest EH, Masson S, McCune A, Patch 
D, Richardson P, Gleeson D, Ryder SD, Wright M, Thursz MR. In Patients With Severe Alcoholic 
Hepatitis, Prednisolone Increases Susceptibility to Infection and Infection-Related Mortality, and Is 
Associated With High Circulating Levels of Bacterial DNA. Gastroenterology 2017; 152: 1068-1077.e4 
[PMID: 28043903 DOI: 10.1053/j.gastro.2016.12.019]
59 Mandrekar P, Szabo G. Signalling pathways in alcohol-induced liver inflammation. J Hepatol 2009; 50: 
1258-1266 [PMID: 19398236 DOI: 10.1016/j.jhep.2009.03.007]
60 Seki E, Brenner DA. Toll-like receptors and adaptor molecules in liver disease: update. Hepatology 2008; 
48: 322-335 [PMID: 18506843 DOI: 10.1002/hep.22306]
61 Li P, He K, Li J, Liu Z, Gong J. The role of Kupffer cells in hepatic diseases. Mol Immunol 2017; 85: 222-
229 [PMID: 28314211 DOI: 10.1016/j.molimm.2017.02.018]
62 Park HS, Jung HY, Park EY, Kim J, Lee WJ, Bae YS. Cutting edge: direct interaction of TLR4 with 
NAD(P)H oxidase 4 isozyme is essential for lipopolysaccharide-induced production of reactive oxygen 
species and activation of NF-kappa B. J Immunol 2004; 173: 3589-3593 [PMID: 15356101 DOI: 
10.4049/jimmunol.173.6.3589]
63 Petrasek J, Mandrekar P, Szabo G. Toll-like receptors in the pathogenesis of alcoholic liver disease. 
Gastroenterol Res Pract 2010; 2010: 710381 [PMID: 20827314 DOI: 10.1155/2010/710381]
Shasthry SM, Sarin SK. New treatment options for alcoholic hepatitis. World J Gastroenterol 2016; 64
Tan HK et al. Oxidative stress in ALD
WJH https://www.wjgnet.com 346 July 27, 2020 Volume 12 Issue 7
22: 3892-3906 [PMID: 27099434 DOI: 10.3748/wjg.v22.i15.3892]
65 Zhang J, Wang X, Vikash V, Ye Q, Wu D, Liu Y, Dong W. ROS and ROS-Mediated Cellular Signaling. 
Oxid Med Cell Longev 2016; 2016: 4350965 [PMID: 26998193 DOI: 10.1155/2016/4350965]
66 Mu W, Liu LZ. Reactive Oxygen Species Signaling in Cancer Development. React Oxyg Species 2017; 4: 
251-265 [DOI: 10.20455/ros.2017.843]
67 Thakur V, Pritchard MT, McMullen MR, Wang Q, Nagy LE. Chronic ethanol feeding increases activation 
of NADPH oxidase by lipopolysaccharide in rat Kupffer cells: role of increased reactive oxygen in LPS-
stimulated ERK1/2 activation and TNF-alpha production. J Leukoc Biol 2006; 79: 1348-1356 [PMID: 
16554353 DOI: 10.1189/jlb.1005613]
68 Cao Q, Mak KM, Lieber CS. Dilinoleoylphosphatidylcholine decreases acetaldehyde-induced TNF-alpha 
generation in Kupffer cells of ethanol-fed rats. Biochem Biophys Res Commun 2002; 299: 459-464 [PMID: 
12445823 DOI: 10.1016/S0006-291X(02)02672-4]
69 McMullen MR, Pritchard MT, Wang Q, Millward CA, Croniger CM, Nagy LE. Early growth response-1 
transcription factor is essential for ethanol-induced fatty liver injury in mice. Gastroenterology 2005; 128: 
2066-2076 [PMID: 15940638 DOI: 10.1053/j.gastro.2005.02.065]
70 Yao J, Mackman N, Edgington TS, Fan ST. Lipopolysaccharide induction of the tumor necrosis factor-
alpha promoter in human monocytic cells. Regulation by Egr-1, c-Jun, and NF-kappaB transcription factors. 
J Biol Chem 1997; 272: 17795-17801 [PMID: 9211933 DOI: 10.1074/jbc.272.28.17795]
71 Kishore R, McMullen MR, Nagy LE. Stabilization of tumor necrosis factor alpha mRNA by chronic 
ethanol: role of A + U-rich elements and p38 mitogen-activated protein kinase signaling pathway. J Biol 
Chem 2001; 276: 41930-41937 [PMID: 11551956 DOI: 10.1074/jbc.M107181200]
72 Win S, Than TA, Zhang J, Oo C, Min RWM, Kaplowitz N. New insights into the role and mechanism of c-
Jun-N-terminal kinase signaling in the pathobiology of liver diseases. Hepatology 2018; 67: 2013-2024 
[PMID: 29194686 DOI: 10.1002/hep.29689]
73 Oak S, Mandrekar P, Catalano D, Kodys K, Szabo G. TLR2- and TLR4-mediated signals determine 
attenuation or augmentation of inflammation by acute alcohol in monocytes. J Immunol 2006; 176: 7628-
7635 [PMID: 16751410 DOI: 10.4049/jimmunol.176.12.7628]
74 Chang Q, Zhang Y, Beezhold KJ, Bhatia D, Zhao H, Chen J, Castranova V, Shi X, Chen F. Sustained JNK1 
activation is associated with altered histone H3 methylations in human liver cancer. J Hepatol 2009; 50: 
323-333 [PMID: 19041150 DOI: 10.1016/j.jhep.2008.07.037]
75 Loomba R, Lawitz E, Mantry PS, Jayakumar S, Caldwell SH, Arnold H, Diehl AM, Djedjos CS, Han L, 
Myers RP, Subramanian GM, McHutchison JG, Goodman ZD, Afdhal NH, Charlton MR; GS-US-384-1497 
Investigators. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, 
phase 2 trial. Hepatology 2018; 67: 549-559 [PMID: 28892558 DOI: 10.1002/hep.29514]
76 Mathurin P, Dufour J-F, Bzowej NH, Shiffman ML, Arterburn S, Nguyen T, Billin A, Chung C, 
Subramanian M, Myers RP, Szabo G, Thevenot T, Cramp ME, Ryder SD, Tilg H, Moreno C, Thursz MR, 
Agarwal K. Selonsertib in combination with prednisolone for the treatment of severe alcoholic hepatitis: a 
phase 2 randomized controlled trial. Hepatology 2018; 68; 8A-9A [DOI: 10.1002/hep.30256]
77 Nogueira V, Hay N. Molecular pathways: reactive oxygen species homeostasis in cancer cells and 
implications for cancer therapy. Clin Cancer Res 2013; 19: 4309-4314 [PMID: 23719265 DOI: 
10.1158/1078-0432.CCR-12-1424]
78 Zhang Y, Du Y, Le W, Wang K, Kieffer N, Zhang J. Redox control of the survival of healthy and diseased 
cells. Antioxid Redox Signal 2011; 15: 2867-2908 [PMID: 21457107 DOI: 10.1089/ars.2010.3685]
79 Zhao Y, Hu X, Liu Y, Dong S, Wen Z, He W, Zhang S, Huang Q, Shi M. ROS signaling under metabolic 
stress: cross-talk between AMPK and AKT pathway. Mol Cancer 2017; 16: 79 [PMID: 28407774 DOI: 
10.1186/s12943-017-0648-1]
80 Latvala J, Hietala J, Koivisto H, Järvi K, Anttila P, Niemelä O. Immune Responses to Ethanol Metabolites 
and Cytokine Profiles Differentiate Alcoholics with or without Liver Disease. Am J Gastroenterol 2005; 
100: 1303-1310 [PMID: 15929761 DOI: 10.1111/j.1572-0241.2005.41509.x]
81 Bird GL, Sheron N, Goka AK, Alexander GJ, Williams RS. Increased plasma tumor necrosis factor in 
severe alcoholic hepatitis. Ann Intern Med 1990; 112: 917-920 [PMID: 2339855 DOI: 
10.7326/0003-4819-112-12-917]
82 Szabo G, Bala S. Alcoholic liver disease and the gut-liver axis. World J Gastroenterol 2010; 16: 1321-1329 
[PMID: 20238398 DOI: 10.3748/wjg.v16.i11.1321]
83 Colmenero J, Bataller R, Sancho-Bru P, Bellot P, Miquel R, Moreno M, Jares P, Bosch J, Arroyo V, 
Caballería J, Ginès P. Hepatic expression of candidate genes in patients with alcoholic hepatitis: correlation 
with disease severity. Gastroenterology 2007; 132: 687-697 [PMID: 17258719 DOI: 
10.1053/j.gastro.2006.12.036]
84 McVicker BL, Tuma DJ, Casey CA. Effect of ethanol on pro-apoptotic mechanisms in polarized hepatic 
cells. World J Gastroenterol 2007; 13: 4960-4966 [PMID: 17854138 DOI: 10.3748/wjg.v13.i37.4960]
85 Neuman MG, Shear NH, Bellentani S, Tiribelli C. Role of cytokines in ethanol-induced cytotoxicity in 
vitro in Hep G2 cells. Gastroenterology 1998; 115: 157-166 [PMID: 9649471 DOI: 
10.1016/S0016-5085(98)70377-4]
86 Micheau O, Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling 
complexes. Cell 2003; 114: 181-190 [PMID: 12887920 DOI: 10.1016/S0092-8674(03)00521-X]
87 Kim YS, Morgan MJ, Choksi S, Liu ZG. TNF-induced activation of the Nox1 NADPH oxidase and its role 
in the induction of necrotic cell death. Mol Cell 2007; 26: 675-687 [PMID: 17560373 DOI: 
10.1016/j.molcel.2007.04.021]
88 Vanden Berghe T, Declercq W, Vandenabeele P. NADPH oxidases: new players in TNF-induced necrotic 
cell death. Mol Cell 2007; 26: 769-771 [PMID: 17588511 DOI: 10.1016/j.molcel.2007.06.002]
Minayoshi Y, Maeda H, Yanagisawa H, Hamasaki K, Mizuta Y, Nishida K, Kinoshita R, Enoki Y, Imafuku 
T, Chuang VTG, Koga T, Fujiwara Y, Takeya M, Sonoda K, Wakayama T, Taguchi K, Ishima Y, Ishida T, 
Iwakiri Y, Tanaka M, Sasaki Y, Watanabe H, Otagiri M, Maruyama T. Development of Kupffer cell 
targeting type-I interferon for the treatment of hepatitis via inducing anti-inflammatory and 
89
Tan HK et al. Oxidative stress in ALD
WJH https://www.wjgnet.com 347 July 27, 2020 Volume 12 Issue 7
immunomodulatory actions. Drug Deliv 2018; 25: 1067-1077 [PMID: 29688069 DOI: 
10.1080/10717544.2018.1464083]
90 Sun B, Karin M. NF-kappaB signaling, liver disease and hepatoprotective agents. Oncogene 2008; 27: 
6228-6244 [PMID: 18931690 DOI: 10.1038/onc.2008.300]
91 Dhanda AD, Yates E, Schewitz-Bowers LP, Lait PJ, Lee RWJ, Cramp ME. Ex Vivo T Cell Cytokine 
Expression Predicts Survival in Patients with Severe Alcoholic Hepatitis. Gut Liver 2020; 14: 265-268 
[PMID: 31158952 DOI: 10.5009/gnl19035]
92 Lemmers A, Moreno C, Gustot T, Maréchal R, Degré D, Demetter P, de Nadai P, Geerts A, Quertinmont E, 
Vercruysse V, Le Moine O, Devière J. The interleukin-17 pathway is involved in human alcoholic liver 
disease. Hepatology 2009; 49: 646-657 [PMID: 19177575 DOI: 10.1002/hep.22680]
93 Orman ES, Odena G, Bataller R. Alcoholic liver disease: pathogenesis, management, and novel targets for 
therapy. J Gastroenterol Hepatol 2013; 28 Suppl 1: 77-84 [PMID: 23855300 DOI: 10.1111/jgh.12030]
94 Kerr IM, Costa-Pereira AP, Lillemeier BF, Strobl B. Of JAKs, STATs, blind watchmakers, jeeps and 
trains. FEBS Lett 2003; 546: 1-5 [PMID: 12829228 DOI: 10.1016/S0014-5793(03)00411-3]
95 Norkina O, Dolganiuc A, Catalano D, Kodys K, Mandrekar P, Syed A, Efros M, Szabo G. Acute alcohol 
intake induces SOCS1 and SOCS3 and inhibits cytokine-induced STAT1 and STAT3 signaling in human 
monocytes. Alcohol Clin Exp Res 2008; 32: 1565-1573 [PMID: 18616672 DOI: 
10.1111/j.1530-0277.2008.00726.x]
96 Tilg H, Moschen AR, Szabo G. Interleukin-1 and inflammasomes in alcoholic liver disease/acute alcoholic 
hepatitis and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology 2016; 64: 955-965 
[PMID: 26773297 DOI: 10.1002/hep.28456]
97 Tschopp J, Schroder K. NLRP3 inflammasome activation: The convergence of multiple signalling 
pathways on ROS production? Nat Rev Immunol 2010; 10: 210-215 [PMID: 20168318 DOI: 
10.1038/nri2725]
98 Revu S, Wu J, Henkel M, Rittenhouse N, Menk A, Delgoffe GM, Poholek AC, McGeachy MJ. IL-23 and 
IL-1β Drive Human Th17 Cell Differentiation and Metabolic Reprogramming in Absence of CD28 
Costimulation. Cell Rep 2018; 22: 2642-2653 [PMID: 29514093 DOI: 10.1016/j.celrep.2018.02.044]
99 Szabo G, Csak T. Inflammasomes in liver diseases. J Hepatol 2012; 57: 642-654 [PMID: 22634126 DOI: 
10.1016/j.jhep.2012.03.035]
100 Takeuchi D, Yoshidome H, Kato A, Ito H, Kimura F, Shimizu H, Ohtsuka M, Morita Y, Miyazaki M. 
Interleukin 18 causes hepatic ischemia/reperfusion injury by suppressing anti-inflammatory cytokine 
expression in mice. Hepatology 2004; 39: 699-710 [PMID: 14999688 DOI: 10.1002/hep.20117]
101 Sakai A, Han J, Cato AC, Akira S, Li JD. Glucocorticoids synergize with IL-1beta to induce TLR2 
expression via MAP Kinase Phosphatase-1-dependent dual Inhibition of MAPK JNK and p38 in epithelial 
cells. BMC Mol Biol 2004; 5: 2 [PMID: 15125785 DOI: 10.1186/1471-2199-5-2]
102 Wintergerst ES, Maggini S, Hornig DH. Contribution of selected vitamins and trace elements to immune 
function. Ann Nutr Metab 2007; 51: 301-323 [PMID: 17726308 DOI: 10.1159/000107673]
103 Zhu H, Jia Z, Misra H, Li YR. Oxidative stress and redox signaling mechanisms of alcoholic liver disease: 
updated experimental and clinical evidence. J Dig Dis 2012; 13: 133-142 [PMID: 22356308 DOI: 
10.1111/j.1751-2980.2011.00569.x]
104 Shah D, Mahajan N, Sah S, Nath SK, Paudyal B. Oxidative stress and its biomarkers in systemic lupus 
erythematosus. J Biomed Sci 2014; 21: 23 [PMID: 24636579 DOI: 10.1186/1423-0127-21-23]
105 Wołonciej M, Milewska E, Roszkowska-Jakimiec W. Trace elements as an activator of antioxidant 
enzymes. Postepy Hig Med Dosw (Online) 2016; 70: 1483-1498 [PMID: 28100855 DOI: 
10.5604/17322693.1229074]
106 Czuczejko J, Zachara BA, Staubach-Topczewska E, Halota W, Kedziora J. Selenium, glutathione and 
glutathione peroxidases in blood of patients with chronic liver diseases. Acta Biochim Pol 2003; 50: 1147-
1154 [PMID: 14740001 DOI: 10.18388/abp.2003_3638]
107 Arakawa Y, Moriyama M, Arakawa Y. Liver cirrhosis and metabolism (sugar, protein, fat and trace 
elements). Hepatol Res 2004; 30S: 46-58 [PMID: 15607139 DOI: 10.1016/j.hepres.2004.10.009]
108 Nangliya V, Sharma A, Yadav D, Sunder S, Nijhawan S, Mishra S. Study of trace elements in liver 
cirrhosis patients and their role in prognosis of disease. Biol Trace Elem Res 2015; 165: 35-40 [PMID: 
25613584 DOI: 10.1007/s12011-015-0237-3]
109 Burk RF, Hill KE, Motley AK, Byrne DW, Norsworthy BK. Selenium deficiency occurs in some patients 
with moderate-to-severe cirrhosis and can be corrected by administration of selenate but not 
selenomethionine: a randomized controlled trial. Am J Clin Nutr 2015; 102: 1126-1133 [PMID: 26468123 
DOI: 10.3945/ajcn.115.110932]
110 Prystupa A, Błażewicz A, Kiciński P, Sak JJ, Niedziałek J, Załuska W. Serum Concentrations of Selected 
Heavy Metals in Patients with Alcoholic Liver Cirrhosis from the Lublin Region in Eastern Poland. Int J 
Environ Res Public Health 2016; 13: 582 [PMID: 27304961 DOI: 10.3390/ijerph13060582]
111 Huang MC, Chen CH, Peng FC, Tang SH, Chen CC. Alterations in oxidative stress status during early 
alcohol withdrawal in alcoholic patients. J Formos Med Assoc 2009; 108: 560-569 [PMID: 19586830 DOI: 
10.1016/S0929-6646(09)60374-0]
112 Saribal D, Hocaoglu-Emre FS, Karaman F, Mırsal H, Akyolcu MC. Trace Element Levels and 
Oxidant/Antioxidant Status in Patients with Alcohol Abuse. Biol Trace Elem Res 2020; 193: 7-13 [PMID: 
30805875 DOI: 10.1007/s12011-019-01681-y]
113 Grüngreiff K, Reinhold D, Wedemeyer H. The role of zinc in liver cirrhosis. Ann Hepatol 2016; 15: 7-16 
[PMID: 26626635 DOI: 10.5604/16652681.1184191]
114 Bode JC, Hanisch P, Henning H, Koenig W, Richter FW, Bode C. Hepatic zinc content in patients with 
various stages of alcoholic liver disease and in patients with chronic active and chronic persistent hepatitis. 
Hepatology 1988; 8: 1605-1609 [PMID: 3192174 DOI: 10.1002/hep.1840080622]
115 Tapiero H, Tew KD. Trace elements in human physiology and pathology: zinc and metallothioneins. 
Biomed Pharmacother 2003; 57: 399-411 [PMID: 14652165 DOI: 10.1016/S0753-3322(03)00081-7]
Wong CP, Rinaldi NA, Ho E. Zinc deficiency enhanced inflammatory response by increasing immune cell 116
Tan HK et al. Oxidative stress in ALD
WJH https://www.wjgnet.com 348 July 27, 2020 Volume 12 Issue 7
activation and inducing IL6 promoter demethylation. Mol Nutr Food Res 2015; 59: 991-999 [PMID: 
25656040 DOI: 10.1002/mnfr.201400761]
117 Hennig B, Meerarani P, Toborek M, McClain CJ. Antioxidant-like properties of zinc in activated 
endothelial cells. J Am Coll Nutr 1999; 18: 152-158 [PMID: 10204831 DOI: 
10.1080/07315724.1999.10718843]
118 Shen H, Arzuaga X, Toborek M, Hennig B. Zinc nutritional status modulates expression of ahr-responsive 
p450 enzymes in vascular endothelial cells. Environ Toxicol Pharmacol 2008; 25: 197-201 [PMID: 
19255596 DOI: 10.1016/j.etap.2007.10.016]
119 Zhong W, Zhao Y, Sun X, Song Z, McClain CJ, Zhou Z. Dietary zinc deficiency exaggerates ethanol-
induced liver injury in mice: involvement of intrahepatic and extrahepatic factors. PLoS One 2013; 8: 
e76522 [PMID: 24155903 DOI: 10.1371/journal.pone.0076522]
120 Zhong W, McClain CJ, Cave M, Kang YJ, Zhou Z. The role of zinc deficiency in alcohol-induced intestinal 
barrier dysfunction. Am J Physiol Gastrointest Liver Physiol 2010; 298: G625-G633 [PMID: 20167873 
DOI: 10.1152/ajpgi.00350.2009]
121 Mohammad MK, Song M, Falkner K, McClain C, Cave M. Zinc Sulfate for Alcoholic Cirrhosis (ZAC) 
Clinical Trial - Interim Analysis of Fiver Injury/Inflammation Biomarkers. Hepatology 2014; 60: 794A 
[DOI: 10.1002/hep.28229]
122 Wenzel G, Kuklinski B, Rühlmann C, Ehrhardt D. [Alcohol-induced toxic hepatitis--a "free radical" 
associated disease. Lowering fatality by adjuvant antioxidant therapy]. Z Gesamte Inn Med 1993; 48: 490-
496 [PMID: 8256468]
123 Pár A, Pár G. [Alcoholic liver disease: the roles of genetic-epigenetic factors and the effect of abstinence]. 
Orv Hetil 2019; 160: 524-532 [PMID: 30931596 DOI: 10.1556/650.2019.31352]
124 Wu Q, Ni X. ROS-mediated DNA methylation pattern alterations in carcinogenesis. Curr Drug Targets 
2015; 16: 13-19 [PMID: 25585126 DOI: 10.2174/1389450116666150113121054]
125 Afanas'ev I. New nucleophilic mechanisms of ros-dependent epigenetic modifications: comparison of aging 
and cancer. Aging Dis 2014; 5: 52-62 [PMID: 24490117 DOI: 10.14336/AD.2014.050052]
126 Boccuto L, Abenavoli L. Genetic and Epigenetic Profile of Patients With Alcoholic Liver Disease. Ann 
Hepatol 2017; 16: 490-500 [PMID: 28612750 DOI: 10.5604/01.3001.0010.0274]
127 Meroni M, Longo M, Rametta R, Dongiovanni P. Genetic and Epigenetic Modifiers of Alcoholic Liver 
Disease. Int J Mol Sci 2018; 19: 3857 [PMID: 30513996 DOI: 10.3390/ijms19123857]
128 Zahs A, Curtis BJ, Waldschmidt TJ, Brown LA, Gauthier TW, Choudhry MA, Kovacs EJ, Bird MD. 
Alcohol and epigenetic changes: summary of the 2011 Alcohol and Immunology Research Interest Group 
(AIRIG) meeting. Alcohol 2012; 46: 783-787 [PMID: 22738858 DOI: 10.1016/j.alcohol.2012.05.005]
129 Kendrick SF, O'Boyle G, Mann J, Zeybel M, Palmer J, Jones DE, Day CP. Acetate, the key modulator of 
inflammatory responses in acute alcoholic hepatitis. Hepatology 2010; 51: 1988-1997 [PMID: 20232292 
DOI: 10.1002/hep.23572]
130 To Y, Ito K, Kizawa Y, Failla M, Ito M, Kusama T, Elliott WM, Hogg JC, Adcock IM, Barnes PJ. 
Targeting phosphoinositide-3-kinase-delta with theophylline reverses corticosteroid insensitivity in chronic 
obstructive pulmonary disease. Am J Respir Crit Care Med 2010; 182: 897-904 [PMID: 20224070 DOI: 
10.1164/rccm.200906-0937OC]
131 Ito K, Caramori G, Adcock IM. Therapeutic potential of phosphatidylinositol 3-kinase inhibitors in 
inflammatory respiratory disease. J Pharmacol Exp Ther 2007; 321: 1-8 [PMID: 17021257 DOI: 
10.1124/jpet.106.111674]
132 Barnes PJ. Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease. J 
Allergy Clin Immunol 2013; 131: 636-645 [PMID: 23360759 DOI: 10.1016/j.jaci.2012.12.1564]
133 Kendrick SF, Henderson E, Palmer J, Jones DE, Day CP. Theophylline improves steroid sensitivity in 
acute alcoholic hepatitis. Hepatology 2010; 52: 126-131 [PMID: 20578267 DOI: 10.1002/hep.23666]
134 Hassanein T, Stein LL, Flamm SL, Martin P, Cave MC, Blevins C, Scott, D, Krebs W, Lin W. Safety and 
efficacy of DUR-928: a potential new therapy for acute alcoholic hepatitis. Hepatology 2019; 70: 1477A-
1501A [DOI: 10.1002/hep.31033]
135 Yu S, Khor TO, Cheung KL, Li W, Wu TY, Huang Y, Foster BA, Kan YW, Kong AN. Nrf2 expression is 
regulated by epigenetic mechanisms in prostate cancer of TRAMP mice. PLoS One 2010; 5: e8579 [PMID: 
20062804 DOI: 10.1371/journal.pone.0008579]
136 Khor TO, Fuentes F, Shu L, Paredes-Gonzalez X, Yang AY, Liu Y, Smiraglia DJ, Yegnasubramanian S, 
Nelson WG, Kong AN. Epigenetic DNA methylation of antioxidative stress regulator NRF2 in human 
prostate cancer. Cancer Prev Res (Phila) 2014; 7: 1186-1197 [PMID: 25266896 DOI: 
10.1158/1940-6207.CAPR-14-0127]
137 Wang D, Ma Y, Yang X, Xu X, Zhao Y, Zhu Z, Wang X, Deng H, Li C, Gao F, Tong J, Yamanaka K, An 
Y. Hypermethylation of the Keap1 gene inactivates its function, promotes Nrf2 nuclear accumulation, and is 
involved in arsenite-induced human keratinocyte transformation. Free Radic Biol Med 2015; 89: 209-219 
[PMID: 26409248 DOI: 10.1016/j.freeradbiomed.2015.07.153]
138 Correa F, Mallard C, Nilsson M, Sandberg M. Activated microglia decrease histone acetylation and Nrf2-
inducible anti-oxidant defence in astrocytes: restoring effects of inhibitors of HDACs, p38 MAPK and 
GSK3β. Neurobiol Dis 2011; 44: 142-151 [PMID: 21757005 DOI: 10.1016/j.nbd.2011.06.016]
139 Guo T, Chang L, Xiao Y, Liu Q. S-adenosyl-L-methionine for the treatment of chronic liver disease: a 
systematic review and meta-analysis. PLoS One 2015; 10: e0122124 [PMID: 25774783 DOI: 
10.1371/journal.pone.0122124]
140 Medici V, Virata MC, Peerson JM, Stabler SP, French SW, Gregory JF 3rd, Albanese A, Bowlus CL, 
Devaraj S, Panacek EA, Richards JR, Halsted CH. S-adenosyl-L-methionine treatment for alcoholic liver 
disease: a double-blinded, randomized, placebo-controlled trial. Alcohol Clin Exp Res 2011; 35: 1960-1965 
[PMID: 22044287 DOI: 10.1111/j.1530-0277.2011.01547.x]
Mato JM, Cámara J, Fernández de Paz J, Caballería L, Coll S, Caballero A, García-Buey L, Beltrán J, 
Benita V, Caballería J, Solà R, Moreno-Otero R, Barrao F, Martín-Duce A, Correa JA, Parés A, Barrao E, 
García-Magaz I, Puerta JL, Moreno J, Boissard G, Ortiz P, Rodés J. S-adenosylmethionine in alcoholic liver 
141
Tan HK et al. Oxidative stress in ALD
WJH https://www.wjgnet.com 349 July 27, 2020 Volume 12 Issue 7
cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol 1999; 30: 
1081-1089 [PMID: 10406187 DOI: 10.1016/S0168-8278(99)80263-3]
142 Collins P, Jones C, Choudhury S, Damelin L, Hodgson H. Increased expression of uncoupling protein 2 in 
HepG2 cells attenuates oxidative damage and apoptosis. Liver Int 2005; 25: 880-887 [PMID: 15998440 
DOI: 10.1111/j.1478-3231.2005.01104.x]
143 Jin X, Yang YD, Chen K, Lv ZY, Zheng L, Liu YP, Chen SH, Yu CH, Jiang XY, Zhang CY, Li YM. 
HDMCP uncouples yeast mitochondrial respiration and alleviates steatosis in L02 and hepG2 cells by 
decreasing ATP and H2O2 levels: a novel mechanism for NAFLD. J Hepatol 2009; 50: 1019-1028 [PMID: 
19303656 DOI: 10.1016/j.jhep.2008.10.034]
144 Cortez-Pinto H, Machado MV. Uncoupling proteins and non-alcoholic fatty liver disease. J Hepatol 2009; 
50: 857-860 [PMID: 19328582 DOI: 10.1016/j.jhep.2009.02.019]
145 Phillips M, Curtis H, Portmann B, Donaldson N, Bomford A, O'Grady J. Antioxidants versus 
corticosteroids in the treatment of severe alcoholic hepatitis--a randomised clinical trial. J Hepatol 2006; 44: 
784-790 [PMID: 16469404 DOI: 10.1016/j.jhep.2005.11.039]
146 Stewart S, Prince M, Bassendine M, Hudson M, James O, Jones D, Record C, Day CP. A randomized trial 
of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis. J Hepatol 2007; 47: 277-283 
[PMID: 17532088 DOI: 10.1016/j.jhep.2007.03.027]
147 Nguyen-Khac E, Thevenot T, Piquet MA, Benferhat S, Goria O, Chatelain D, Tramier B, Dewaele F, Ghrib 
S, Rudler M, Carbonell N, Tossou H, Bental A, Bernard-Chabert B, Dupas JL; AAH-NAC Study Group. 
Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis. N Engl J Med 2011; 365: 1781-1789 
[PMID: 22070475 DOI: 10.1056/NEJMoa1101214]
148 European Association for the Study of the Liver; Thursz M, Gual A, Lackner C, Mathurin P, Moreno C, 
Spahr L, Sterneck M, Cortez-Pinto H. European Association for the Study of the Liver. EASL Clinical 
Practice Guidelines: Management of alcohol-related liver disease. J Hepatol 2018; 69: 154-181 [PMID: 
29628280 DOI: 10.1016/j.jhep.2018.03.018]
149 McClain C, Vatsalya V, Cave M. Role of Zinc in the Development/Progression of Alcoholic Liver Disease. 
Curr Treat Options Gastroenterol 2017; 15: 285-295 [PMID: 28447197 DOI: 10.1007/s11938-017-0132-4]
150 Singh AK, Bishayee A, Pandey AK. Targeting Histone Deacetylases with Natural and Synthetic Agents: An 
Emerging Anticancer Strategy. Nutrients 2018; 10: 731 [PMID: 29882797 DOI: 10.3390/nu10060731]
Published by Baishideng Publishing Group Inc 
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA 
Telephone: +1-925-3991568 
E-mail: bpgoffice@wjgnet.com 
Help Desk: https://www.f6publishing.com/helpdesk 
https://www.wjgnet.com
© 2020 Baishideng Publishing Group Inc. All rights reserved.
